CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Operating expenses:
Research and development	$ 3,218	$ 7,124
General and administrative	4,504	5,104
Total operating expenses	7,722	12,228
Loss from operations	(7,722)	(12,228)
Other income	113	1,197
Total other income	113	1,197
Net loss and comprehensive loss	$ (7,609)	$ (11,031)
Net loss per share - basic	$ (0.54)	$ (0.9)
Net loss per share - diluted	$ (0.54)	$ (0.9)
Weighted-average common shares - basic	14,095,371	12,197,615
Weighted-average common shares - diluted	14,095,371	12,197,615